Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Cytosorbents Q3 2026 Results: Net Loss of $2.05M, Loss Narrows

CytoSorbents reported a net loss of $12.0 million for the nine months ended September 30, 2026, compared to a $2.7 million loss in the prior year period, primarily driven by a significant negative swing in foreign currency transaction gains/losses. Total revenue remained relatively stable at $28.2 million, while the company implemented a 1-for-20 reverse stock split in September 2026.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue9.79.5
Gross profit7.36.7
Profit before tax-2.1-3.6
Net income-2.1-3.2
EPS (diluted, $ a share)$-0.65$-1.01

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+2.6%
Gross margin75.3%
Operating margin-12.0%
Source

10-Q filed with the SEC, NASDAQ: CTSO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Cytosorbents Corp: key numbers

Share price
$4.16Close, Nov 20
Market cap
$16.2M
Shares outstanding
3.15MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cytosorbents Corp

All →
8:57 AM ET 8-K
Capital Raise

Cytosorbents Capital Raise of $4M

CytoSorbents announced a $4.0 million registered direct offering of common stock and pre-funded warrants, with approximately 75% of the offering subscribed for by existing shareholders and management. The proceeds will be used to repay $3.0 million of outstanding principal under the company's loan agreement with Avenue Capital Group as part of a broader debt restructuring.

Value
$4M
Counterparty
H.C. Wainwright & Co., LLC
7:22 AM ET 8-K/A
Financial Results

Cytosorbents Financial Results

Cytosorbents Corp reported Q3 2026 financial results, achieving its goal of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, driven by an 18% increase in distributor and strategic partner sales, while the net loss narrowed to $2.1 million.

Term
Q3 2026

“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”

Dr. Phillip Chan, Chief Executive Officer
4:17 PM ET 8-K
Financial Results

Cytosorbents Financial Results

CytoSorbents reported Q3 2026 financial results, highlighting the achievement of operating cash flow breakeven (excluding restructuring payments). Revenue grew 3% to $9.7 million, while operating loss improved by 59% to $1.2 million due to disciplined cost management and improved gross margins.

Term
Q3 2026

“The third quarter marked an important financial milestone for CytoSorbents as we achieved our goal of operating cash flow breakeven, excluding restructuring-related payments. This achievement reflects a year of disciplined execution and meaningful improvements in our underlying business.”

Dr. Phillip Chan, Chief Executive Officer
7:31 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Cytosorbents Nasdaq/NYSE Compliance Notice

CytoSorbents has regained compliance with Nasdaq's $1.00 minimum bid price requirement after its stock closed at or above that level for 10 consecutive trading sessions. However, the company remains non-compliant with the $35 million Minimum Market Value of Listed Securities (MVLS) requirement and has until December 28, 2026, to resolve this deficiency.

Counterparty
Nasdaq
Term
until Dec 28, 2026
5:31 PM ET Form 4
Insider Buying

Cytosorbents CEO Phillip P. Chan Buys $22.6K of Stock

Phillip P. Chan, CEO, bought 3,774 shares of Cytosorbents Corp at $6.00 a share, worth $22.6K in total on Sep 15, 2026. Shares held after the trade: 100,996 (+3.9%).

Value
$22.6K
Shares
3,774
Price
$6.00
Role
CEO
Holding change
+3.9%
Trade date
Sep 15, 2026
4:06 PM ET Form 4
Insider Buying

Cytosorbents President and COO Vincent Capponi Buys $10.9K of Stock

Vincent Capponi, President and COO, bought 1,800 shares of Cytosorbents Corp at $6.07 a share, worth $10.9K in total on Sep 14, 2026. Shares held after the trade: 40,114 (+4.7%).

Value
$10.9K
Shares
1,800
Price
$6.07
Role
President and COO
Holding change
+4.7%
Trade date
Sep 14, 2026

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.